Protocol Details BPC-157 and TB-500 are administered via subcutaneous injection, typically on a daily or alternating-day schedule depending on the severity of the condition
22 Hohmann E, Tetsworth K, Glatt V
Caution: Although BCP-157 shows promising potential in many areas, it is important to note that research is still in early stages, and its long-term effects have not been fully studied
Contact us at The Sculptique Aesthetics
Injectable forms remain the benchmark for consistent systemic exposure, though local or compartmental activity may be feasible for some molecules designed for oral stability
If a dose is missed, patients could apply it when remembered on the same day or resume the regular schedule at the next planned administration-double dosing is not recommended